Editorial: Insulin delivery via lungs-is it still possible?

Diabetes Technology and Therapeutics

Volumn 11, Issue SUPPL. 2, 2009, Pages

  Garg, Satish K ^a   Kelly, William C ^b  

^a UNIVERSITY OF COLORADO DENVER   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AIR INHALED INSULIN; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN; INSULIN GLARGINE; INSULIN LISPRO; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT;

ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; EDITORIAL; FEMALE; GLYCEMIC CONTROL; HEADACHE; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; DRUG EFFECT; INHALATIONAL DRUG ADMINISTRATION; LUNG; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY;

ADMINISTRATION, INHALATION; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LUNG;

EID: 70349466484     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/dia.2009.0088     Document Type: Editorial

References (16)

1. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulindependent diabetes mellitus. The Diabetes Control and Complication Trial Research Group. N Engl J Med 993;329: 977-986.
2. Writing Team for the Diabetes Control and Complication Trial=Epidemiology of Diabetes Interventions and Complications Research Study: Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetes nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 2003;290:2159-2167.
3. Nathan,DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B; Diabetes Control and Complications Trial=Epidemiology of Diabetes Interventions and Complications (DCCT=EDIC) Study Research Group: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005:353:2643-2653.
4. Hogan P, Dall T, Nikolov P; American Diabetes Association: Economic costs of diabetes in the US in 2002. Diabetes Care 2003;26:917-932.
5. American Diabetes Association: Economic costs of diabetes in the US in 2007. Diabetes Care 2008;31:1-20.
6. Ettaro L, Songer TJ, Zhang P, Engelgau MM: Cost-of-illness studies in diabetes mellitus. Pharmacoeconomics 2004;22: 140-164.
7. Garg SK, Skyler JS: Continuous Glucose Monitoring (CGM) Supplement.Diabetes Technol Ther 2007;9(Suppl 1):S-1-S-132.
8. Skyler JS: Pulmonary insulin delivery-state of the art 2007. Diabetes Technol Ther 2007;9(Suppl 1):S-1-S-3.
9. Hirsch IB: Arguments against the use of inhaled insulin. Diabetes Technol Ther 2007;9(Suppl 1):S-111-S-114.
10. Heubner W, De Jongh SE, Laquer E: Über Inhalation von Insulin. Klin Wochenscher 1924;3:2342-2343.
11. Gansslein M:Über Inhalation von Insulin. Klin Wochenscher 1925;4:71.
12. Heubner W: Über Inhalation, Insbesondere von Insulin. MA nch Med Wochenschr 1925;67:244-245.
13. Inhalation of insulin. JAMA 1925;84:634.
14. Silten E: Bemerkkungen zur Technik der Insulininhalation. Med Klin 1925;35:1309.
15. Palm A: Versuche Über Inhalation von Insulin. Z Ges Exp Med 1927;55:432-444.
16. Wilkoewitz K, Schiebe H: Die Wirkung der Insulininhalation bei Atmungsvertiefung Durch Kohlensäure. Z Ges Exp Med 1931;78:757-763.